The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Therapeutic target database 2020: enriched resource for facilitating research and early development of targeted therapeutics
Open accessAbstract
Knowledge of therapeutic targets and early drug candidates is useful for improved drug discovery. In particular, information about target regulators and the patented therapeutic agents facilitates research regarding druggability, systems pharmacology, new trends, molecular landscapes, and the development of drug discovery tools. To complement other databases, we constructed the Therapeutic Target Database (TTD) with expanded information about (i) target-regulating microRNAs and transcription factors, (ii) target-interacting proteins, and (iii) patented agents and their targets (structures and experimental activity values if available), which can be conveniently retrieved and is further enriched with regulatory mechanisms or biochemical classes. We also updated the TTD with the recently released International Classification of Diseases ICD-11 codes and additional sets of successful, clinical trial, and literature-reported targets that emerged since the last update. TTD is accessible at http://bidd.nus.edu.sg/group/ttd/ttd.asp. In case of possible web connectivity issues, two mirror sites of TTD are also constructed (http://db.idrblab.org/ttd/ and http://db.idrblab.net/ttd/).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
DrugBank 5.0: a major update to the DrugBank database for 2018
Wishart, D. S., Feunang, Y. D., Guo, A. C., Lo, E. J., Marcu, A., Grant, J. R., Sajed, T., Johnson, D., Li, C., Sayeeda, Z., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1037 · Cited by 8,404
Li, J.-H., Liu, S., Zhou, H., Qu, L.-H., & Yang, J.-H. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1248 · Cited by 4,686
Network pharmacology: the next paradigm in drug discovery
Hopkins, A. L. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.118 · Cited by 4,622
PubChem 2019 update: improved access to chemical data
Kim, S., Chen, J., Cheng, T., Gindulyte, A., He, J., He, S., Li, Q., Shoemaker, B. A., Thiessen, P. A., Yu, B., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1033 · Cited by 3,249
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S. S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,476
Self-citationA comprehensive map of molecular drug targets
Santos, R., Ursu, O., Gaulton, A., Bento, A. P., Donadi, R. S., Bologa, C. G., Karlsson, A., Al-Lazikani, B., Hersey, A., Oprea, T. I., et al. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.230 · Cited by 2,427
ChEMBL: towards direct deposition of bioassay data
Mendez, D., Gaulton, A., Bento, A. P., Chambers, J., De Veij, M., Félix, E., Magariños, M. P., Mosquera, J. F., Mutowo, P., Nowotka, M., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1075 · Cited by 2,372
The Database of Interacting Proteins: 2004 update
Salwinski, L. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh086 · Cited by 2,271
Aptamers as targeted therapeutics: current potential and challenges
Zhou, J., & Rossi, J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.199 · Cited by 2,221
TRANSFAC(R) and its module TRANSCompel(R): transcriptional gene regulation in eukaryotes
Matys, V. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj143 · Cited by 2,166
New approach for understanding genome variations in KEGG
Kanehisa, M., Sato, Y., Furumichi, M., Morishima, K., & Tanabe, M. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky962 · Cited by 1,845
miRTarBase update 2018: a resource for experimentally validated microRNA-target interactions
Chou, C.-H., Shrestha, S., Yang, C.-D., Chang, N.-W., Lin, Y.-L., Liao, K.-W., Huang, W.-C., Sun, T.-H., Tu, S.-J., Lee, W.-H., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1067 · Cited by 1,811
Miotto, R., Li, L., Kidd, B. A., & Dudley, J. T. (2016) · Scientific Reports · doi:10.1038/srep26094 · Cited by 1,710 · cited 1×
“The International Classification of Diseases (ICD) is a health statistics and diagnostics coding tool for describing human disease conditions (65), and it has been applied to other applications such as the development of artificial intelligence diagnostic tools (66).”
MethodHarding, S. D., Sharman, J. L., Faccenda, E., Southan, C., Pawson, A. J., Ireland, S., Gray, A. J. G., Bruce, L., Alexander, S. P. H., Anderton, S., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1121 · Cited by 1,646
Gilson, M. K., Liu, T., Baitaluk, M., Nicola, G., Hwang, L., & Chong, J. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1072 · Cited by 1,628
Why is Tanimoto index an appropriate choice for fingerprint-based similarity calculations?
Bajusz, D., Rácz, A., & Héberger, K. (2015) · Journal of Cheminformatics · doi:10.1186/s13321-015-0069-3 · Cited by 1,621
Deep learning enables rapid identification of potent DDR1 kinase inhibitors
Zhavoronkov, A., Ivanenkov, Y. A., Aliper, A., Veselov, M. S., Aladinskiy, V. A., Aladinskaya, A. V., Terentiev, V. A., Polykovskiy, D. A., Kuznetsov, M. D., Asadulaev, A., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0224-x · Cited by 1,573 · cited 1×
“The structural and activity data of patented agents are useful for such tasks as the study of discovery landscapes and opportunities (34,35), as well as the development of artificial intelligence tools (36).”
BackgroundThe BioGRID interaction database: 2019 update
Oughtred, R., Stark, C., Breitkreutz, B.-J., Rust, J., Boucher, L., Chang, C., Kolas, N., O’Donnell, L., Leung, G., McAdam, R., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1079 · Cited by 1,473
An analysis of the attrition of drug candidates from four major pharmaceutical companies
Waring, M. J., Arrowsmith, J., Leach, A. R., Leeson, P. D., Mandrell, S., Owen, R. M., Pairaudeau, G., Pennie, W. D., Pickett, S. D., Wang, J., et al. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4609 · Cited by 1,450
Lessons from 60 years of pharmaceutical innovation
Munos, B. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2961 · Cited by 1,207
A Global Map of p53 Transcription-Factor Binding Sites in the Human Genome
Wei, C.-L., Wu, Q., Vega, V. B., Chiu, K. P., Ng, P., Zhang, T., Shahab, A., Yong, H. C., Fu, Y., Weng, Z., et al. (2006) · Cell · doi:10.1016/j.cell.2005.10.043 · Cited by 1,141 · cited 1×
“These experiments include electrophoretic mobility shift assays (53), chromatin immunoprecipitations (54), DNase footprinting assays (55), and so on.”
BackgroundDIANA-TarBase v8: a decade-long collection of experimentally supported miRNA–gene interactions
Karagkouni, D., Paraskevopoulou, M. D., Chatzopoulos, S., Vlachos, I. S., Tastsoglou, S., Kanellos, I., Papadimitriou, D., Kavakiotis, I., Maniou, S., Skoufos, G., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1141 · Cited by 1,135
Southan, C., Sharman, J. L., Benson, H. E., Faccenda, E., Pawson, A. J., Alexander, S. P. H., Buneman, O. P., Davenport, A. P., McGrath, J. C., Peters, J. A., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1037 · Cited by 1,035
The druggable genome and support for target identification and validation in drug development
Finan, C., Gaulton, A., Kruger, F. A., Lumbers, R. T., Shah, T., Engmann, J., Galver, L., Kelley, R., Karlsson, A., Santos, R., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aag1166 · Cited by 1,026
Mechanisms of drug combinations: interaction and network perspectives
Jia, J., Zhu, F., Ma, X., Cao, Z. W., Li, Y. X., & Chen, Y. Z. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2683 · Cited by 969
Self-citationThe BioGRID interaction database: 2017 update
Chatr-aryamontri, A., Oughtred, R., Boucher, L., Rust, J., Chang, C., Kolas, N. K., O'Donnell, L., Oster, S., Theesfeld, C., Sellam, A., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1102 · Cited by 965
Transcriptional Regulatory Elements in the Human Genome
Maston, G. A., Evans, S. K., & Green, M. R. (2006) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.7.080505.115623 · Cited by 937 · cited 1×
“They have been used for probing the direct binding of a TF to the promoter, enhancer or silencer region of a target gene, thus leading to the initiation (56), increase (57) or repression of the transcription of the studied gene (58), respectively.”
MethodDrugging the ‘undruggable’ cancer targets
Dang, C. V., Reddy, E. P., Shokat, K. M., & Soucek, L. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.36 · Cited by 927
The efficiency of multi-target drugs: the network approach might help drug design
CSERMELY, P., AGOSTON, V, & PONGOR, S. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.02.007 · Cited by 803 · cited 1×
“microRNAs, transcription factors and interacting proteins) is useful for drug discovery tasks (Supplementary Table S1) such as the investigations of target druggability (6,30), systems pharmacology (31) and the discovery of multi-target and combination therapies (32,33).”
BackgroundThe influence of lead discovery strategies on the properties of drug candidates
Keserü, G. M., & Makara, G. M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2796 · Cited by 628
Enhancers: five essential questions
Pennacchio, L. A., Bickmore, W., Dean, A., Nobrega, M. A., & Bejerano, G. (2013) · Nature Reviews Genetics · doi:10.1038/nrg3458 · Cited by 589
Liu, Z.-P., Wu, C., Miao, H., & Wu, H. (2015) · Database · doi:10.1093/database/bav095 · Cited by 555
Li, Y. H., Yu, C. Y., Li, X. X., Zhang, P., Tang, J., Yang, Q., Fu, T., Zhang, X., Cui, X., Tu, G., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1076 · Cited by 523
Self-citationOpen Targets: a platform for therapeutic target identification and validation
Koscielny, G., An, P., Carvalho-Silva, D., Cham, J. A., Fumis, L., Gasparyan, R., Hasan, S., Karamanis, N., Maguire, M., Papa, E., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1055 · Cited by 504
Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery
Zhu, F., Shi, Z., Qin, C., Tao, L., Liu, X., Xu, F., Zhang, L., Song, Y., Liu, X., Zhang, J., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr797 · Cited by 480
Self-citationOpen Targets Platform: new developments and updates two years on
Carvalho-Silva, D., Pierleoni, A., Pignatelli, M., Ong, C., Fumis, L., Karamanis, N., Carmona, M., Faulconbridge, A., Hercules, A., McAuley, E., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1133 · Cited by 472
Drugging an undruggable pocket on KRAS
Kessler, D., Gmachl, M., Mantoulidis, A., Martin, L. J., Zoephel, A., Mayer, M., Gollner, A., Covini, D., Fischer, S., Gerstberger, T., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1904529116 · Cited by 449
Wingender, E. (2008) · Briefings in Bioinformatics · doi:10.1093/bib/bbn016 · Cited by 435
Systems Pharmacology: Network Analysis to Identify Multiscale Mechanisms of Drug Action
Zhao, S., & Iyengar, R. (2012) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134520 · Cited by 358
Trial Reporting in ClinicalTrials.gov — The Final Rule
Zarin, D. A., Tse, T., Williams, R. J., & Carr, S. (2016) · New England Journal of Medicine · doi:10.1056/nejmsr1611785 · Cited by 332 · cited 1×
“gov (70), and the corresponding disease indications and NCT numbers were confirmed; third, the target antigen of each CAR-T therapy was identified using ClinicalTrials.”
BackgroundNeish, A. S., Read, M. A., Thanos, D., Pine, R., Maniatis, T., & Collins, T. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.5.2558 · Cited by 298
Computer Review of ChemDraw Ultra 12.0
Cousins, K. R. (2011) · Journal of the American Chemical Society · doi:10.1021/ja204075s · Cited by 297
Xue, W., Yang, F., Wang, P., Zheng, G., Chen, Y., Yao, X., & Zhu, F. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00490 · Cited by 288
Self-citationYang, H., Qin, C., Li, Y. H., Tao, L., Zhou, J., Yu, C. Y., Xu, F., Chen, Z., Zhu, F., & Chen, Y. Z. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1230 · Cited by 270
Self-citationSureChEMBL: a large-scale, chemically annotated patent document database
Papadatos, G., Davies, M., Dedman, N., Chambers, J., Gaulton, A., Siddle, J., Koks, R., Irvine, S. A., Pettersson, J., Goncharoff, N., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1253 · Cited by 229
Yang, Q., Li, B., Tang, J., Cui, X., Wang, Y., Li, X., Hu, J., Chen, Y., Xue, W., Lou, Y., et al. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbz049 · Cited by 217
Self-citationMicroRNA regulates human vitamin D receptor
Mohri, T., Nakajima, M., Takagi, S., Komagata, S., & Yokoi, T. (2009) · International Journal of Cancer · doi:10.1002/ijc.24459 · Cited by 209
Global microRNA level regulation of EGFR‐driven cell‐cycle protein network in breast cancer
Uhlmann, S., Mannsperger, H., Zhang, J. D., Horvat, E., Schmidt, C., Küblbeck, M., Henjes, F., Ward, A., Tschulena, U., Zweig, K., et al. (2012) · Molecular Systems Biology · doi:10.1038/msb.2011.100 · Cited by 202
Two-tailed RT-qPCR: a novel method for highly accurate miRNA quantification
Androvic, P., Valihrach, L., Elling, J., Sjoback, R., & Kubista, M. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx588 · Cited by 198
MicroRNAs in cancer: from developmental genes in worms to their clinical application in patients
Pichler, M., & Calin, G. A. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.253 · Cited by 191
Pathogenesis of the Limb Manifestations and Exercise Limitations in Peripheral Artery Disease
Hiatt, W. R., Armstrong, E. J., Larson, C. J., & Brass, E. P. (2015) · Circulation Research · doi:10.1161/circresaha.116.303566 · Cited by 187
Therapeutic Targets: Progress of Their Exploration and Investigation of Their Characteristics
Zheng, C. J., Han, L. Y., Yap, C. W., Ji, Z. L., Cao, Z. W., & Chen, Y. Z. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.2.4 · Cited by 185
Self-citationLancet, T. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31205-x · Cited by 183
Li, Y., Li, X. X., Hong, J. J., Wang, Y., Fu, J., Yang, H. J., Yu, C. Y., Li, F., Hu, J., Xue, W., et al. (2018) · Briefings in Bioinformatics · doi:10.1093/bib/bby130 · Cited by 162
Self-citationUsing reverse docking for target identification and its applications for drug discovery
Lee, A., Lee, K., & Kim, D. (2016) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2016.1190706 · Cited by 151
Ursu, O., Holmes, J., Bologa, C., Yang, J. J., Mathias, S. L., Stathias, V., Nguyễn, Ð.-T., Schürer, S. C., & Oprea, T. I. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky963 · Cited by 150
Rangasamy, S. B., Jana, M., Roy, A., Corbett, G. T., Kundu, M., Chandra, S., Mondal, S., Dasarathi, S., Mufson, E. J., Mishra, R. K., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96209 · Cited by 139
Mullard, A. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.4 · Cited by 137
Epigenetic polypharmacology: A new frontier for epi‐drug discovery
Tomaselli, D., Lucidi, A., Rotili, D., & Mai, A. (2019) · Medicinal Research Reviews · doi:10.1002/med.21600 · Cited by 136
Kawauchi, J., Zhang, C., Nobori, K., Hashimoto, Y., Adachi, M. T., Noda, A., Sunamori, M., & Kitajima, S. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202974200 · Cited by 131
MicroRNA pharmacogenomics: Post-transcriptional regulation of drug response
Rukov, J. L., & Shomron, N. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.04.003 · Cited by 127
Wang, T., Wu, X., Guo, C., Zhang, K., Xu, J., Li, Z., & Jiang, S. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00990 · Cited by 124
Mishra, P. J., Song, B., Mishra, P. J., Wang, Y., Humeniuk, R., Banerjee, D., Merlino, G. T., Ju, J., & Bertino, J. R. (2009) · PLoS ONE · doi:10.1371/journal.pone.0008445 · Cited by 114
Self-citationPolypharmacology-based ceritinib repurposing using integrated functional proteomics
Kuenzi, B. M., Rix, L. L. R., Stewart, P. A., Fang, B., Kinose, F., Bryant, A. T., Boyle, T. A., Koomen, J. M., Haura, E. B., & Rix, U. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2489 · Cited by 103
MicroRNA-223 protects neurons from degeneration in experimental autoimmune encephalomyelitis
Morquette, B., Juźwik, C. A., Drake, S., Charabati, M., Zhang, Y., Lécuyer, M., Galloway, D. A., Dumas, A., de Faria, O., Paradis-Isler, N., et al. (2019) · Brain · doi:10.1093/brain/awz245 · Cited by 91
Self-citationQuantitative systems-level determinants of human genes targeted by successful drugsPreprint
Yao, L., & Rzhetsky, A. (2007) · Genome Research · doi:10.1101/gr.6888208 · Cited by 89
Johnson, C. W., Lin, Y.-J., Reid, D., Parker, J., Pavlopoulos, S., Dischinger, P., Graveel, C., Aguirre, A. J., Steensma, M., Haigis, K. M., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.07.026 · Cited by 89
VARIDT 1.0: variability of drug transporter database
Yin, J., Sun, W. C., Li, F., Hong, J., Li, X., Zhou, Y., Lu, Y., Liu, M., Zhang, X. Z., Chen, N., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz878 · Cited by 77
Self-citationccmGDB: a database for cancer cell metabolism genes
Kim, P., Cheng, F., Zhao, J., & Zhao, Z. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv1128 · Cited by 61
Wang, C., Hu, G., Wang, K., Bryliński, M., Xie, L., & Kurgan, L. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btv597 · Cited by 48
CancerResource—updated database of cancer-relevant proteins, mutations and interacting drugs
Gohlke, B.-O., Nickel, J., Otto, R., Dunkel, M., & Preißner, R. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv1283 · Cited by 41
Li, X. X., Yin, J., Tang, J., Li, Y., Yang, Q., Xiao, Z., Zhang, R., Wang, Y., Hong, J., Tao, L., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01245 · Cited by 40
Self-citationFranchini, P., Xiong, P., Fruciano, C., Schneider, R., Woltering, J. M., Hulsey, C. D., & Meyer, A. (2019) · Molecular Biology and Evolution · doi:10.1093/molbev/msz168 · Cited by 39
Gene promoters show chromosome-specificity and reveal chromosome territories in humans
Gagniuc, P. A., & Ionescu-Tirgoviste, C. (2013) · BMC Genomics · doi:10.1186/1471-2164-14-278 · Cited by 25
Yang, Q., Zhang, Y., Cui, H. S., Chen, L., Zhao, Y., Lin, Y., Zhang, M., & Xie, L. (2018) · Database · doi:10.1093/database/bay015 · Cited by 24
Self-citationGene expression as a target for new drug discovery.
Heguy, A., Aa, S., Jd, H., De, S., & Foulkes, J. G. (1995) · Europe PMC (PubMed Central) · Cited by 22
Cited by
Large-scale integration of the plasma proteome with genetics and disease
Ferkingstad, E., Sulem, P., Atlason, B. A., Sveinbjornsson, G., Magnusson, M. I., Styrmisdottir, E. L., Gunnarsdottir, K., Helgason, A., Oddsson, A., Halldorsson, B. V., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00978-w · Cited by 1,697
Integration of the Drug–Gene Interaction Database (DGIdb 4.0) with open crowdsource efforts
Freshour, S. L., Kiwala, S., Cotto, K. C., Coffman, A. C., McMichael, J. F., Song, J. J., Griffith, M., Griffith, O. L., & Wagner, A. H. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkaa1084 · Cited by 998
HERB: a high-throughput experiment- and reference-guided database of traditional Chinese medicine
Fang, S., Dong, L., Liu, L., Guo, J., Zhao, L., Zhang, J., Bu, D., Liu, X., Huo, P., Cao, W., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkaa1063 · Cited by 690
Zhou, Y., Zhang, Y., Lian, X., Li, F., Wang, C., Zhu, F., Qiu, Y., & Chen, Y. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkab953 · Cited by 665
Self-citationTTD: Therapeutic Target Database describing target druggability information
Zhou, Y., Zhang, Y., Zhao, D., Yu, X., Shen, X., Zhou, Y., Wang, S., Qiu, Y., Chen, Y., & Zhu, F. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkad751 · Cited by 645
Self-citation
Metadata
- Authors
- Wang, Y., Zhang, S., Li, F., Zhou, Y., Zhang, Y., Wang, Z., Zhang, R., Zhu, J., Ren, Y., Tan, Y., Qin, C., Li, Y., Li, X., Chen, Y., & Zhu, F.
- Venue
- Nucleic Acids Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-11-06
- Volume
- 48
- Issue
- D1
- Pages
- D1031-D1041
- ISSN
- 0305-1048 (ISSN-L)
- 1362-4962
- OpenAlex
- W2987928072
- Cited by
- 794
- References
- 78
- FWCI
- 82.02
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.